11/20
01:33 pm
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:07 am
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
11/14
08:26 am
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at BTIG Research from $42.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at BTIG Research from $42.00 to $44.00. They now have a "buy" rating on the stock.
11/8
07:41 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership [Yahoo! Finance]
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership [Yahoo! Finance]
11/6
07:00 am
rnac
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
10/30
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Medium
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
10/30
07:00 am
rnac
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
Medium
Report
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
10/3
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grant
Low
Report
Cartesian Therapeutics Announces New Employment Inducement Grant